Table 2.

Patients' characteristics within groups “early” and “late”.

	Group “Early”	Group “Late”	p Value
Pre-treatment PSA*	13.9 ng/mL (9.43)	21.85 ng/mL (26.32)	0.83
T stageΨ			0.69
1c	4/22 (18%)	5/32 (16%)
2a-c	11/22 (50%)	20/32 (63%)
3a-b	7/22 (32%)	7/32 (22%)
Gleason score*	6.6 (0.58)	6.73 (1.04)	0.76
median (range)	3+4 (3+3 to 4+3)	3+4 (2+3 to 5+4)
D'Amico's risk groupΨ			0.33
high	10/25 (40%)	16/34 (47%)
intermediate	10/25 (40%)	16/34 (47%)
low	5/25 (20%)	2 (6%)
Radiation dose*	75.5 Gy (3.27)	74.3 Gy (3.73)	0.31
Hormonal therapyΨ	13/25 (52%)	15/34 (44%)	0.60
Biochemical failureΨ	7/25 (28%)	15/34 (44%)	0.28

^*= mean (standard deviation)

^Ψ= n (percentage).